Sai Life Sciences shares made a strong debut on December 18, 2024. On BSE, the stock listed at Rs 660, a 20.2% premium over the issue price of Rs 549. On NSE, it opened at Rs 650, reflecting an 18.3% premium.
Also Read: IT stock hits 10% upper circuit after company’s promoter to sell 6.5% stake via OFS
Sai Life Sciences’ Rs 3,042.62 crore IPO, with a price band of Rs 522-549 and a lot size of 27 shares, opened on December 11 and closed on December 13, 2024, with a subscription of 10.26 times. QIBs led with 30.90 times demand.
Sai Life Sciences Limited offers comprehensive drug discovery, development, and manufacturing services globally. With advanced facilities in India and research hubs in the US and UK, the company specializes in complex drug manufacturing and prioritizes sustainability and high ESG standards.
The objective of Sai Life Sciences’ IPO is to raise funds for repaying debts, enhancing its manufacturing facilities, and supporting the company’s growth strategy. The proceeds will also be used for general corporate purposes and strengthening its financial position.
Disclaimer: The above article is written for educational purposes, and the companies’ data mentioned in the article may change with respect to time The securities quoted are exemplary and are not recommendatory.